reason report
higher growth profil reflect broad biolog
bottom line remain outperform-r given view
compani life scienc tool lst leader unmatch scale
reach research lab market combin number growth
product serv key end-market grow consolid posit
deliv impress quarter guid reflect
total organ growth year bp ahead target
compani maintain past believ compani uniqu
lever growth biolog biomolecular drug multipl point
drug discoveri drug product give outstand growth
profil portfolio continu deliv across board though
see stronger y/i growth compar still believ
abl maintain growth momentum in-lin past
quarter rais pt
strong growth broad base across major end-market
like continu key segment includ life scienc
lab product servic lp contribut strength
quarter averag organ growth across key segment
despit solid comp given sheer size posit lst
market investor believ like pay closer attent tougher
compar emerg tariff overhang continu despit
limit impact far believ could deliv growth
gener dri powder avail execut deal drive
growth accret model long-term
growth china except minim impact
tariff china deliv anoth quarter growth reflect
opportun technolog continu see region
materi scienc biolog drug research believ
investor like watch tariff close despit suggest
impact tariff year plan off-set
continu see growth china find challeng replac
high-end technolog includ chrom mass spec fei electron
guid rais still conserv vs perform deliv
far year believ conserv guidanc
revis strength first quarter exceed expect
compani forecast full-year organ revenu growth
ep growth estim reflect higher revenu
growth organ expect vs
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquir view
consolid sizabl portion lst market patheon acquisit close
believ potenti consolid contract develop manufactur
organ industri long term view posit given sheer
scale reput presenc lst market biopharma academ channel
industrial/environment diagnost deliv manag forecast grow
solidifi presenc emerg market asia-pacif china revenu
continu strength biopharma end-market view sign slow
near term inorgan growth continu remain key prioriti next five
year capit deploy estim suggest debt/
share current trade ev/ebitda larg in-lin large-
mid-cap tool averag ev/ebitda
given impress growth deliv last quarter leverag
biolog drug discoveri develop product china emerg market tailwind
still continu believ hold posit lead lab tool suppli
provid like continu post strong growth expect trade
premium large- mid-cap tool averag ev/ebitda multipl deliv ev/
ebitda result deriv price target appli multipl
ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report leerink partner estim
